ICER Chief Scientific Officer Bradt Brings Pharma Perspective
Executive Summary
Pamela Brandt joins health technology assessment group after stints at Aegerion, Astellas and Abbott Labs.
You may also be interested in...
Price ‘Anchoring’? Zolgensma And The Art Of Managing Gene Therapy Sticker Shock
Public statements by Novartis and AveXis suggest Zolgensma could be cost effective at a price up to $5m. Analysts expect $2m. The lower estimate is still stunning, but could it be considered reasonable by comparison?
ICER’s ‘Unsupported Price Increase’ Report Due This Fall
Report by the Institute for Clinical and Economic Review will seek to inform the public policy debate on price increases for prescription drugs.
Medicare Reimbursement For Part B Drugs Is 48% Above 340B Prices To Hospitals, MedPAC Finds
New study updates past commission analyses and highlights the significant margin between Medicare payments for drugs and the prices paid by 340B-eligible providers.